ROVI announces the agreement with Sandoz to distribute and market its Enoxaparin biosimilar


No votes yet
 
Related
Download our press release published on 20 February to find out the financial results for the full year 2017.
1 min
20/02/2018
Operating income, growth figures, profitability and how our products have behaved.
1 min
20/02/2018
0 min
21/12/2017